Media Kit

Reach Out to Our Media Contacts

Contact Avanir Corporate Communications:

You may use the multimedia material provided in this section only for your personal use or for purposes such as news reporting, teaching, scholarship or research. The images may not be modified and must display a copyright notice in the name of Avanir Pharmaceuticals, Inc. (Copyright © Avanir Pharmaceuticals, Inc).

Listing

2020-07-08

Avanir Pharmaceuticals Honored as ASCP Hall of Fame Award Winner

2020-06-16

University of California Irvine's Paul Merage School of Business Announces Avanir Pharmaceuticals CEO and CFO Join Advisory Board of Center for Health Care Management and Policy

2019-11-18

Avanir Pharmaceuticals and Alzheimer's Orange County Partner for 2019 Walk4ALZ and Run4ALZ to Fight Alzheimer's and Dementia

2019-11-11

Avanir Pharmaceuticals, Inc. to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia

2019-09-27

Avanir Pharmaceuticals, Inc. Reports Data from the Second Phase 3 Study Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia

2019-09-26

Avanir Pharmaceuticals Announces Resolution of Government Investigation

2019-03-24

Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia

2019-02-12

Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules

2018-12-10

Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail®

2018-04-20

Avanir Pharmaceuticals Launches New Campaign to Educate Patients and Caregivers by Raising Awareness of the Appropriate Diagnosis and Treatment of PseudoBulbar Affect (PBA).

Downloads

LOGO - Avanir Pharmaceuticals

LOGO - NUEDEXTA®

Listing

Funding & Support

As part of our commitment to improving patient care, we offer funding to healthcare providers and other stakeholders to advance the field of CNS conditions.

Learn More

Our Pipeline

We’re always looking forward to the next step: Delivering hope through tangible solutions for patients suffering from central nervous system (CNS) conditions.

Learn More

Leadership Team

We have a passion for patients, based on our own personal experiences. When combined with scientific ingenuity and a commitment to transparency, we offer real solutions to those we serve.

Learn More

MLR-AVN-US-0335-0220